Generation of potentially inhibitory autoantibodies to ADAMTS13 in coronavirus disease 2019.

Autor: Doevelaar AAN; Medical Department 1, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Hölkeskampring 40, 44625, Herne, Germany., Bachmann M; Department of Intensive Care and Ventilatory Medicine, Asklepios Klinikum Hamburg Harburg, Hamburg, Germany., Hölzer B; Medical Department 1, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Hölkeskampring 40, 44625, Herne, Germany., Seibert FS; Medical Department 1, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Hölkeskampring 40, 44625, Herne, Germany., Rohn BJ; Medical Department 1, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Hölkeskampring 40, 44625, Herne, Germany., Zgoura P; Medical Department 1, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Hölkeskampring 40, 44625, Herne, Germany., Witzke O; Department of Infectiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Dittmer U; Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Brenner T; Department of Anesthesiology and Intensive Care Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Paniskaki K; Department of Infectiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.; Center for Translational Medicine, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany., Yilmaz S; Department of Intensive Care and Ventilatory Medicine, Asklepios Klinikum Hamburg Harburg, Hamburg, Germany., Dittmer R; Department of Hemostaseology, MEDILYS Laborgesellschaft mbH, Hamburg, Germany., Schneppenheim S; Department of Hemostaseology, MEDILYS Laborgesellschaft mbH, Hamburg, Germany., Wilhelm J; Department of Hemostaseology, MEDILYS Laborgesellschaft mbH, Hamburg, Germany., Stervbo U; Center for Translational Medicine, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany., Babel N; Center for Translational Medicine, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany., Budde U; Department of Hemostaseology, MEDILYS Laborgesellschaft mbH, Hamburg, Germany., Westhoff TH; Medical Department 1, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Hölkeskampring 40, 44625, Herne, Germany. Timm.Westhoff@elisabethgruppe.de.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2023 Jun 28; Vol. 13 (1), pp. 10501. Date of Electronic Publication: 2023 Jun 28.
DOI: 10.1038/s41598-023-37405-5
Abstrakt: It has recently been shown that von Willebrand factor (VWF) multimers contribute to immunothrombosis in Coronavirus disease 2019 (COVID-19). Since COVID-19 is associated with an increased risk of autoreactivity, the present study investigates, whether the generation of autoantibodies to ADAMTS13 contributes to this finding. In this observational prospective controlled multicenter study blood samples and clinical data of patients hospitalized for COVID-19 were collected from April to November 2020. The study included 156 individuals with 90 patients having confirmed COVID-19 of mild to critical severity. 30 healthy individuals and 36 critically ill ICU patients without COVID-19 served as controls. ADAMTS13 antibodies occurred in 31 (34.4%) COVID-19 patients. Antibodies occurred more often in critically ill COVID-19 patients (55.9%) than non-COVID-19 ICU patients and healthy controls (5.6% and 6.7%; p < 0.001), respectively. Generation of ADAMTS13 antibodies in COVID-19 was associated with lower ADAMTS13 activity (56.5%, interquartile range (IQR) 21.25 vs. 71.5%, IQR 24.25, p = 0.0041), increased disease severity (severe or critical in 90% vs. 62.3%, p = 0.019), and a trend to higher mortality (35.5% vs. 18.6%, p = 0.077). Median time to antibody development was 11 days after first positive SARS-CoV-2-PCR specimen. Gel analysis of VWF multimers resembled the constellation in patients with TTP. The present study demonstrates for the first time, that generation of ADAMTS13 antibodies is frequent in COVID-19, associated with lower ADAMTS13 activity and increased risk of an adverse disease course. These findings provide a rationale to include ADAMTS13 antibodies in the diagnostic workup of SARS-CoV-2 infections.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje